awmsg logo



doxylamine succinate/pyridoxine hydrochloride (Xonvea®)


Reference No. 2170


Appraisal information

doxylamine succinate/pyridoxine hydrochloride (Xonvea®) 10 mg/10 mg film-coated tablet


Company: Alliance Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: 03/04/2019
AWMSG meeting date: 15/05/2019
   
   
Submission Type: Full Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of nausea and vomiting of pregnancy in those patients who do not respond to conservative management
AWMSG Secretariat Appraisal Report (ASAR)
Download
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download